PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20856911-5 2010 In recent years, a new, safe, and efficacious armamentarium of treatment options has been provided by the marketing of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, a peripheral blocker of dopa to 3-0-methyldopa metabolism, which increments levodopa brain availability. Dihydroxyphenylalanine 206-210 catechol-O-methyltransferase Homo sapiens 123-151 20856911-5 2010 In recent years, a new, safe, and efficacious armamentarium of treatment options has been provided by the marketing of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, a peripheral blocker of dopa to 3-0-methyldopa metabolism, which increments levodopa brain availability. Dihydroxyphenylalanine 206-210 catechol-O-methyltransferase Homo sapiens 153-157 17069061-1 2006 Based on literature data on the usage of Dopa medications in the treatment of Parkinson"s disease (PD), a characteristic of a new complex drug stalevo, which includes levodopa, carbidopa and entacapon (catechol-O-methyltransferase inhibitor), is presented. Dihydroxyphenylalanine 41-45 catechol-O-methyltransferase Homo sapiens 202-230 15340869-1 2004 Two catechol- O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were developed during the 1990"s to be used as adjuncts to levodopa (LD) - dopa decarboxylase (DDC) inhibitors in the treatment of Parkinson"s disease (PD). Dihydroxyphenylalanine 142-146 catechol-O-methyltransferase Homo sapiens 35-39 11233302-7 2001 At present, supplement of dopamine by levodopa administration, retarding the metabolism of levodopa or dopamine by a dopa decarboxylase inhibitor (DCI), MAO-B (monoamine oxidase inhibitor type B) inhibitor or catechol-O-methyltransferase (COMT) inhibitor, dopamine receptor agonists, anticholinergic agents, dopamine release enhancer/uptake inhibitor, N-methyl-D-aspartate (NMDA) receptor antagonists are applied for the treatment of Parkinson"s disease. Dihydroxyphenylalanine 26-30 catechol-O-methyltransferase Homo sapiens 209-237 11233302-7 2001 At present, supplement of dopamine by levodopa administration, retarding the metabolism of levodopa or dopamine by a dopa decarboxylase inhibitor (DCI), MAO-B (monoamine oxidase inhibitor type B) inhibitor or catechol-O-methyltransferase (COMT) inhibitor, dopamine receptor agonists, anticholinergic agents, dopamine release enhancer/uptake inhibitor, N-methyl-D-aspartate (NMDA) receptor antagonists are applied for the treatment of Parkinson"s disease. Dihydroxyphenylalanine 26-30 catechol-O-methyltransferase Homo sapiens 239-243 8911671-3 1996 This localization suggests a functional relationship between COMT and AADC with regard to the metabolism of DOPA. Dihydroxyphenylalanine 108-112 catechol-O-methyltransferase Homo sapiens 61-65 8255368-6 1993 There seems to be a close relationship between the time-course of plasma concentrations of CGP 28,014 and the extent of COMT inhibition assessed by the 30MD/DOPA ratio in plasma. Dihydroxyphenylalanine 157-161 catechol-O-methyltransferase Homo sapiens 120-124 1875781-2 1991 The mean soluble COMT activities with 3,4-dihydroxybenzoic acid (DBA) and 3,4-dihydroxyphenylalanine (L-DOPA) as substrate were 70-242 and 70-174 pmol/min mg, respectively. Dihydroxyphenylalanine 74-100 catechol-O-methyltransferase Homo sapiens 17-21 2501825-10 1989 The antitremor effect of Dopa is potentiated by catechol-O-methyltransferase inhibition, suggesting a therapeutic potential for these types of agents. Dihydroxyphenylalanine 25-29 catechol-O-methyltransferase Homo sapiens 48-76 3111485-1 1987 [18F]-6-Fluoro-L-DOPA ([18F]DOPA), a tracer for cerebral dopamine in studies utilizing positron emission tomography (PET), is rapidly metabolized by catechol-O-methyltransferase (COMT) in the periphery following intravenous injection to carbidopa-pretreated humans and rats. Dihydroxyphenylalanine 17-21 catechol-O-methyltransferase Homo sapiens 149-177 3111485-1 1987 [18F]-6-Fluoro-L-DOPA ([18F]DOPA), a tracer for cerebral dopamine in studies utilizing positron emission tomography (PET), is rapidly metabolized by catechol-O-methyltransferase (COMT) in the periphery following intravenous injection to carbidopa-pretreated humans and rats. Dihydroxyphenylalanine 17-21 catechol-O-methyltransferase Homo sapiens 179-183 3927916-0 1985 The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents. Dihydroxyphenylalanine 64-86 catechol-O-methyltransferase Homo sapiens 97-125 3927916-0 1985 The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents. Dihydroxyphenylalanine 88-92 catechol-O-methyltransferase Homo sapiens 97-125 3927916-1 1985 The three ring-fluorinated analogs of dihydroxyphenylalanine (DOPA) were synthesized and the kinetics of their O-methylation catalyzed by catechol-O-methyltransferase compared to those of DOPA. Dihydroxyphenylalanine 38-60 catechol-O-methyltransferase Homo sapiens 138-166 3927916-1 1985 The three ring-fluorinated analogs of dihydroxyphenylalanine (DOPA) were synthesized and the kinetics of their O-methylation catalyzed by catechol-O-methyltransferase compared to those of DOPA. Dihydroxyphenylalanine 62-66 catechol-O-methyltransferase Homo sapiens 138-166 6783056-2 1981 1 A sensitive radioenzymatic assay was developed, in which DOPA is enzymatically decarboxylated to dopamine and the latter converted to [3H]-methoxytyramine in the presence of [3H]-S-adenosyl-L-methionine and catechol-o-methyltransferase. Dihydroxyphenylalanine 59-63 catechol-O-methyltransferase Homo sapiens 209-237 6780660-2 1981 The method is based on the conversion of DOPA to 3-O-[methyl-3H]DOPA by catechol-O-methyltransferase in the presence of S-adenosyl-[methyl-3H]methionine and purification of the labelled product by Sephadex G10 and Dowex 50 W x 4 ion exchange resin. Dihydroxyphenylalanine 41-45 catechol-O-methyltransferase Homo sapiens 72-100 6782443-0 1981 Phenol ionization in dopa determines the site of methylation by catechol-O-methyltransferase. Dihydroxyphenylalanine 21-25 catechol-O-methyltransferase Homo sapiens 64-92 709823-3 1978 DOPA decarboxylase is used to convert DOPA to dopamine, which concurrently is converted to [3H]-3-O-methyldopamine in the presence of catechol-O-methyltransferase and [methyl-3H]-S-adenosylmethionine and assayed radioenzymatically. Dihydroxyphenylalanine 0-4 catechol-O-methyltransferase Homo sapiens 134-162